Lurbinectedin, marketed under the brand name Zepzelca, is a prescription medication used to treat metastatic small cell lung cancer. According to Drugs.com [2], the cost of Zepzelca is approximately $4,600 for a 4-milliliter vial, which is equivalent to a single dose. The total cost of treatment will depend on the dosage prescribed and the length of treatment.

DrugPatentWatch [1] reports that the patent for lurbinectedin is set to expire in October 2037. This suggests that generic versions of the drug may not be available until after that date. As a result, the cost of Zepzelca may remain high until then.

The FDA label for Zepzelca [3] does not provide any information on the cost of the drug. However, it does note that the recommended dosage is 3.2 mg/m2 administered as an intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity. The label also provides information on potential side effects and warnings associated with the use of the drug.

In summary, Zepzelca (lurbinectedin) is a prescription medication used to treat metastatic small cell lung cancer. The cost of the drug is approximately $4,600 for a single dose, and the total cost of treatment will depend on the dosage prescribed and the length of treatment. While the patent for lurbinectedin is set to expire in October 2037, the cost of the drug may remain high until generic versions become available. The FDA label for Zepzelca provides information on the recommended dosage, potential side effects, and warnings associated with the use of the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.drugs.com/price-guide/zepzelca
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf